Filings Worth Watching: Bb Biotech Ag Has Boosted Its Holding in Incyte Corp. (INCY) by $3.71 Million

Filings Worth Watching: Bb Biotech Ag Has Boosted Its Holding in Incyte Corp. (INCY) by $3.71 Million

Bb Biotech Ag increased its stake in Incyte Corp. (INCY) by 1.03% based on its latest 2016Q3 regulatory filing with the SEC. Bb Biotech Ag bought 39,416 shares as the company’s stock rose 16.02% with the market. The institutional investor held 3.88 million shares of the commercial physical & biological resarch company at the end of 2016Q3, valued at $365.83M, up from 3.84 million at the end of the previous reported quarter. Bb Biotech Ag who had been investing in Incyte Corp. for a number of months, seems to be bullish on the $22.62 billion market cap company. The stock closed at $119.3 during the last session. It is down 44.71% since June 7, 2016 and is uptrending. It has outperformed by 37.29% the S&P500.

Insitutional Activity: The institutional sentiment decreased to 1.15 in Q3 2016. Its down 0.04, from 1.19 in 2016Q2. The ratio dived, as 33 funds sold all INCY shares owned while 122 reduced positions. 56 funds bought stakes while 123 increased positions. They now own 171.33 million shares or 0.40% less from 172.01 million shares in 2016Q2. Moreover, Gulf State Bank (Uk) Ltd has 0.08% invested in Incyte Corporation (NASDAQ:INCY) for 50,575 shares. Pub Employees Retirement Association Of Colorado holds 0.03% or 35,468 shares in its portfolio. Ashford Capital Mngmt Inc owns 117,419 shares or 2.28% of their US portfolio. Bancorporation Of Mellon Corporation holds 0.02% of its portfolio in Incyte Corporation (NASDAQ:INCY) for 683,062 shares. Zurcher Kantonalbank (Zurich Cantonalbank) owns 36,745 shares or 0.04% of their US portfolio. Principal Gru holds 0% of its portfolio in Incyte Corporation (NASDAQ:INCY) for 39,118 shares. Synovus Corp has 0.02% invested in the company for 8,012 shares. The California-based Shelton Capital has invested 0.1% in Incyte Corporation (NASDAQ:INCY). Edgewood Mngmt Ltd holds 0% of its portfolio in Incyte Corporation (NASDAQ:INCY) for 3,585 shares. Invesco holds 0.07% of its portfolio in Incyte Corporation (NASDAQ:INCY) for 2.16 million shares. Natl Planning holds 0.06% of its portfolio in Incyte Corporation (NASDAQ:INCY) for 7,712 shares. Nippon Life Insur holds 0.03% or 13,176 shares in its portfolio. Brown Advisory last reported 66,248 shares in the company. Voya Inv Llc has 0.01% invested in the company for 72,507 shares. Capital Intl Ca holds 1.09% of its portfolio in Incyte Corporation (NASDAQ:INCY) for 96,937 shares.

Insider Transactions: Since July 29, 2016, the stock had 0 insider buys, and 8 selling transactions for $13.79 million net activity. Huber Reid M sold $879,600 worth of Incyte Corporation (NASDAQ:INCY) on Tuesday, August 2. SWAIN PAULA J also sold $1.80 million worth of Incyte Corporation (NASDAQ:INCY) shares. Another trade for 24,204 shares valued at $2.35 million was sold by Flannelly Barry P.

More recent Incyte Corporation (NASDAQ:INCY) news were published by: which released: “3 Biggest Risks for Incyte Corporation” on December 17, 2016. Also published the news titled: “Incyte and Merck to Advance Clinical Development Program Investigating the …” on January 09, 2017.‘s news article titled: “The Most Likely Incyte Acquisition Deal for 2017?” with publication date: December 23, 2016 was also an interesting one.

According to Zacks Investment Research, “Incyte Corp is a drug discovery company that is using its expertise in genomics, medicinal chemistry and molecular, cellular and in vivo biology to discover and develop novel therapeutics. The company has three fully-staffed drug discovery programs underway focused primarily on the identification of new small molecule drugs for cancer and inflammation. Incyte also has strategic alliances with Lexicon Genetics and Medarex focused on the discovery and development of protein therapeutics or antibodies to treat inflammatory diseases and cancer.”

Incyte Corporation (NASDAQ:INCY) Ratings Coverage

Out of 19 analysts covering Incyte (NASDAQ:INCY), 17 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 89% are positive. Incyte has been the topic of 39 analyst reports since August 6, 2015 according to StockzIntelligence Inc. JP Morgan maintained it with “Overweight” rating and $118 target price in Thursday, September 3 report. The stock of Incyte Corporation (NASDAQ:INCY) has “Outperform” rating given on Wednesday, July 13 by RBC Capital Markets. The rating was maintained by Leerink Swann with “Outperform” on Tuesday, February 16. The stock has “Overweight” rating given by Morgan Stanley on Wednesday, March 23. As per Wednesday, August 5, the company rating was maintained by Brean Capital. The rating was maintained by JMP Securities with “Market Outperform” on Monday, October 10. The firm has “Outperform” rating given on Monday, November 9 by Oppenheimer. On Thursday, August 13 the stock rating was initiated by Barclays Capital with “Overweight”. Barclays Capital maintained it with “Overweight” rating and $85 target price in Friday, February 12 report. The rating was initiated by BMO Capital Markets on Thursday, April 7 with “Outperform”.

INCY Company Profile

Incyte Corporation, incorporated on April 8, 1991, is a biopharmaceutical company. The Firm is focused on the discovery, development and commercialization of therapeutics to treat medical needs, primarily in oncology. The Firm focuses on the research and development program to explore the inhibition of enzymes called janus associated kinases (JAK). The Company’s pipeline includes compounds in various stages, ranging from preclinical to late stage development, and a commercialized product, JAKAFI (ruxolitinib). The Firm has discovered multiple potent, selective and orally bioavailable JAK inhibitors that are selective for JAK1 or JAK1 and JAK2. JAKAFI is the compound in its JAK program, which is an oral JAK1 and JAK2 inhibitor. JAKAFI orphan drug is indicated for Myelofibrosis (MF), Polycythemia Vera (PV) and essential thrombocythemia.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Leave a Reply

Be the First to Comment!

Notify of